↓ Skip to main content

Dove Medical Press

Article Metrics

Update on optimal use of lisdexamfetamine in the treatment of ADHD

Overview of attention for article published in Neuropsychiatric Disease and Treatment, July 2013
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (59th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
60 Mendeley
Title
Update on optimal use of lisdexamfetamine in the treatment of ADHD
Published in
Neuropsychiatric Disease and Treatment, July 2013
DOI 10.2147/ndt.s34092
Pubmed ID
Authors

Vishal Madaan, Venkata Kolli, Durga Bestha, Manan Shah

Abstract

Lisdexamfetamine (LDX) has been a recent addition to the treatment armamentarium for Attention Deficit Hyperactivity Disorder (ADHD). It is unique among stimulants as it is a prodrug, and has been found to be safe and well-tolerated medication in children older than 6 years, adolescents and adults. It has a smooth onset of action, exerts its action up to 13 hours and may have less rebound symptoms. LDX has proven to be effective in the treatment of ADHD in placebo controlled trials, and improved performance in simulated academic and work environments have been noticed. Both stimulant-naïve and stimulant-exposed patients with ADHD appear to benefit from LDX. It has also shown some promise in improving emotional expression and executive function of patients with ADHD. Adverse effects such as decrease in sleep, loss of appetite and others have been reported with LDX use, just as with other stimulant formulations. Since most such studies exclude subjects with preexisting cardiac morbidity, prescribing precautions should be taken with LDX in such subjects, as with any other stimulant. Study subjects on LDX have been reported to have low scores on drug likability scales, even with intravenous use; as a result, LDX may have somewhat less potential for abuse and diversion. There is a need for future studies comparing other long acting stimulants with LDX in ADHD; in fact clinical trials comparing LDX with OROS (osmotic controlled-release oral delivery system) methylphenidate are currently underway. Furthermore, the utility of this medication in other psychiatric disorders and beyond ADHD is being investigated.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 5%
Brazil 2 3%
Unknown 55 92%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 20%
Unspecified 10 17%
Student > Bachelor 8 13%
Student > Master 6 10%
Student > Ph. D. Student 6 10%
Other 18 30%
Readers by discipline Count As %
Medicine and Dentistry 20 33%
Psychology 15 25%
Unspecified 11 18%
Agricultural and Biological Sciences 4 7%
Social Sciences 3 5%
Other 7 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 September 2013.
All research outputs
#1,927,121
of 4,507,280 outputs
Outputs from Neuropsychiatric Disease and Treatment
#411
of 908 outputs
Outputs of similar age
#35,541
of 90,513 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#39
of 64 outputs
Altmetric has tracked 4,507,280 research outputs across all sources so far. This one has received more attention than most of these and is in the 56th percentile.
So far Altmetric has tracked 908 research outputs from this source. They receive a mean Attention Score of 3.3. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 90,513 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.
We're also able to compare this research output to 64 others from the same source and published within six weeks on either side of this one. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.